Abstract
T-cell large granular lymphocyte (LGL) leukemia is a rare indolent neoplasm primarily treated with immunosuppression. Few therapies and no consensus exist for the optimal treatment of T-cell LGL leukemia refractory to immunosuppressive therapy. Here, we report a case of relapsed/refractory T-cell LGL treated with belinostat. A 57-year-old male presented with lymphocytosis and anemia and was found to have T-cell LGL, requiring frequent packed red blood cell transfusions. He was initially treated with methotrexate with no response after 7 months. He was then switched to cyclosporine and cyclophosphamide and experienced transfusion independence for 42 months before disease relapse. He was then started on belinostat with noted subsequent transfusion independence for greater than 15 months to date and decreased disease involvement on bone marrow biopsy. To our knowledge, this is the first reported case of belinostat use in relapsed/refractory T-cell LGL leukemia which resulted in a durable clinical and biologic response.
References
1.
Shah
MV
, Hook
CC
, Call
TG
, Go
RS
. A population-based study of large granular lymphocyte leukemia
. Blood Cancer J
. 2016
Aug
;6
(8
):e455
.
[PubMed]
2044-53852.
Lamy
T
, Loughran
TP
Jr. Clinical features of large granular lymphocyte leukemia
. Semin Hematol
. 2003
Jul
;40
(3
):185
–95
.
[PubMed]
0037-19633.
Dhodapkar
MV
, Li
CY
, Lust
JA
, Tefferi
A
, Phyliky
RL
. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
Blood
. 1994
Sep
;84
(5
):1620
–7
.
[PubMed]
0006-49714.
Lamy
T
, Loughran
TP
Jr. How I treat LGL leukemia
. Blood
. 2011
Mar
;117
(10
):2764
–74
.
[PubMed]
0006-49715.
Lamy
T
, Moignet
A
, Loughran
TP
Jr. LGL leukemia: from pathogenesis to treatment
. Blood
. 2017
Mar
;129
(9
):1082
–94
.
[PubMed]
0006-49716.
Gazitt
T
, Loughran
TP
Jr. Chronic neutropenia in LGL leukemia and rheumatoid arthritis
. Hematology (Am Soc Hematol Educ Program)
. 2017
Dec
;2017
(1
):181
–6
.
[PubMed]
1520-43917.
Sokol
L
, Loughran
TP
Jr. Large granular lymphocyte leukemia
. Oncologist
. 2006
Mar
;11
(3
):263
–73
.
[PubMed]
1083-71598.
Moignet
A
, Lamy
T
. Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia
. Am Soc Clin Oncol Educ Book
. 2018
May
;38
(38
):616
–25
.
[PubMed]
1548-87489.
Loughran
TP
Jr, Kidd
PG
, Starkebaum
G
. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate
. Blood
. 1994
Oct
;84
(7
):2164
–70
.
[PubMed]
0006-497110.
Bareau
B
, Rey
J
, Hamidou
M
, Donadieu
J
, Morcet
J
, Reman
O
, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases
. Haematologica
. 2010
Sep
;95
(9
):1534
–41
.
[PubMed]
0390-607811.
Loughran
TP
Jr, Zickl
L
, Olson
TL
, Wang
V
, Zhang
D
, Rajala
HL
, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)
. Leukemia
. 2015
Apr
;29
(4
):886
–94
.
[PubMed]
0887-692412.
Gabor
EP
, Mishalani
S
, Lee
S
. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia
. Blood
. 1996
Feb
;87
(3
):1199
–200
.
[PubMed]
0006-497113.
Battiwalla
M
, Melenhorst
J
, Saunthararajah
Y
, Nakamura
R
, Molldrem
J
, Young
NS
, et al. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders
. Br J Haematol
. 2003
Nov
;123
(3
):449
–53
.
[PubMed]
0007-104814.
Osuji
N
, Matutes
E
, Tjonnfjord
G
, Grech
H
, Del Giudice
I
, Wotherspoon
A
, et al. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature
. Cancer
. 2006
Aug
;107
(3
):570
–8
.
[PubMed]
0008-543X15.
Moignet
A
, Hasanali
Z
, Zambello
R
, Pavan
L
, Bareau
B
, Tournilhac
O
, et al. Cyclophosphamide as a first-line therapy in LGL leukemia
. Leukemia
. 2014
May
;28
(5
):1134
–6
.
[PubMed]
0887-692416.
Mohan
SR
, Maciejewski
JP
. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia
. Curr Opin Hematol
. 2009
Jan
;16
(1
):27
–34
.
[PubMed]
1065-625117.
Osuji
N
, Del Giudice
I
, Matutes
E
, Morilla
A
, Owusu-Ankomah
K
, Morilla
R
, et al. CD52 expression in T-cell large granular lymphocyte leukemia—implications for treatment with alemtuzumab
. Leuk Lymphoma
. 2005
May
;46
(5
):723
–7
.
[PubMed]
1042-819418.
Fortune
AF
, Kelly
K
, Sargent
J
, O’Brien
D
, Quinn
F
, Chadwick
N
, et al. Large granular lymphocyte leukemia: natural history and response to treatment
. Leuk Lymphoma
. 2010
May
;51
(5
):839
–45
.
[PubMed]
1042-819419.
Rosenblum
MD
, LaBelle
JL
, Chang
CC
, Margolis
DA
, Schauer
DW
, Vesole
DH
. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia
. Blood
. 2004
Mar
;103
(5
):1969
–71
.
[PubMed]
0006-497120.
Dumitriu
B
, Ito
S
, Feng
X
, Stephens
N
, Yunce
M
, Kajigaya
S
, et al. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study
. Lancet Haematol
. 2016
Jan
;3
(1
):e22
–9
.
[PubMed]
2352-302621.
Zaja
F
, Baldini
L
, Ferreri
AJ
, Luminari
S
, Grossi
A
, Salvi
F
, et al. Bendamustine salvage therapy for T cell neoplasms
. Ann Hematol
. 2013
Sep
;92
(9
):1249
–54
.
[PubMed]
0939-555522.
Rosamilio
R
, Giudice
V
, Ferrara
I
, Annunziata
S
, Pezzullo
L
, Villani
G
, et al. Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment
. Transl Med UniSa
. 2016
Nov
;15
:80
–3
.
[PubMed]
2239-974723.
Sternberg
A
, Eagleton
H
, Pillai
N
, Leyden
K
, Turner
S
, Pearson
D
, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity
. Br J Haematol
. 2003
Feb
;120
(4
):699
–701
.
[PubMed]
0007-104824.
Subbiah
V
, Viny
AD
, Rosenblatt
S
, Pohlman
B
, Lichtin
A
, Maciejewski
JP
. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia
. Exp Hematol
. 2008
Sep
;36
(9
):1078
–83
.
[PubMed]
0301-472X25.
Marks
PA
, Richon
VM
, Rifkind
RA
. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells
. J Natl Cancer Inst
. 2000
Aug
;92
(15
):1210
–6
.
[PubMed]
0027-887426.
Lee
HZ
, Kwitkowski
VE
, Del Valle
PL
, Ricci
MS
, Saber
H
, Habtemariam
BA
, et al. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
. Clin Cancer Res
. 2015
Jun
;21
(12
):2666
–70
.
[PubMed]
1078-043227.
O’Connor
OA
, Horwitz
S
, Masszi
T
, Van Hoof
A
, Brown
P
, Doorduijn
J
, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
. J Clin Oncol
. 2015
Aug
;33
(23
):2492
–9
.
[PubMed]
0732-183X28.
Sawas
A
, Radeski
D
, O’Connor
OA
. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
. Ther Adv Hematol
. 2015
Aug
;6
(4
):202
–8
.
[PubMed]
2040-6207© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
